[Federal Register Volume 68, Number 22 (Monday, February 3, 2003)]
[Notices]
[Pages 5293-5294]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-2393]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Nucleic Acid Vaccines for 
Prevention of Flavivirus Infection

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide exclusive 
license to practice the inventions embodied in the patents and patent 
applications referred to below to Fort Dodge Animal Health, a Division 
of Wyeth, located in Overland Park, Kansas. The patent rights in these 
inventions have been assigned to the government of the United States of 
America. The patents and patent applications to be licensed are:
    Title:

U.S. Patent Application SN 60/087,908 entitled ``Nucleic Acid Vaccines 
for Prevention of Flavivirus Infection,'' filed 5.13.1999. And related 
applications: PCT/US99/12298, filed 6.3.1999; U.S. Patent Application 
SN 09/701,536; and all foreign applications listed in Appendix A. CDC 
reference No. I-008-97
U.S. Patent application SN 09/826,115 entitled ``Nucleic Acid Vaccines 
for Prevention of Flavivirus Infection,'' filed 4.4.2001. And related 
application PCT/US02/10764 filed 4.4.2002. CDC reference No. I-001-01

    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    This invention covers a recombinant DNA vaccine candidate for the 
prevention of flavivirus. Licensee will further develop this vaccine 
candidate for use as an animal vaccine.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments, and other materials relating

[[Page 5294]]

to the contemplated license should be directed to Andrew Watkins, 
Director, Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 
30341, telephone: (770) 488-8600; facsimile: (770) 488-8615. 
Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. Only 
written comments and/or applications for a license which are received 
by CDC within sixty days of this notice will be considered. Comments 
and objections submitted in response to this notice will not be made 
available for public inspection, and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552. A signed Confidential Disclosure Agreement will be required to 
receive a copy of any pending patent application.

    Dated: January 27, 2003.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 03-2393 Filed 1-31-03; 8:45 am]
BILLING CODE 4163-18-P